

Press release
30 March, 2023

Resolutions of the Annual General Meeting of Curasight A/S

Curasight A/S, CVR no. 35 24 93 89 (“Curasight” or the “Company”) held its Annual General Meeting on 30 March 2023 at 10:00 (CET) at the Company’s premises, Ole Maaløes Vej 3, room M3.10, DK-2200 Copenhagen N, Denmark.

Today, Curasight A/S (“Curasight” or the “Company”) adopted the following resolutions at its Annual General Meeting:

Presentation and approval of the annual report

The General Meeting adopted the annual report for the financial year 2022.

Appropriation of profit or covering of loss as recorded in the adopted annual report

The General Meeting adopted the Board of Directors’ proposal to carry forward the result for 2022 to the next year in accordance with the adopted annual report for 2022.

Election of members to the Board of Directors

The General Meeting re-elected the following members of the Board of Directors:

- Per Falholt
- Lars Trolle
- Andreas Kjær
- Charlotte Vedel
- Kirsten Aarup Drejer
- Ulrich Krasilnikoff

Election of auditor

The General Meeting re-elected PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab as auditor of the Company.

Authorisation to the chairman of the meeting

The General Meeting adopted a resolution to authorise the chairman of the meeting to apply for registration of the resolutions passed and to make certain amendments, if necessary.



PROVIDING ANSWERS FOR CANCER PATIENTS

At the board meeting held immediately after the Annual General Meeting, Per Falholt was re-elected chairman and Lars Trolle vice-chairman of the Board of Directors.

For more information regarding Curasight, please contact:

Ulrich Krasilnikoff, CEO

Phone: +45 22 83 01 60

E-mail: uk@curasight.com

www.curasight.com

Curasight is a clinical development company based in Copenhagen, Denmark. The company is a pioneer in the field of exploiting a novel Positron Emissions Tomography (PET) imaging platform targeting the urokinase-type plasminogen activator receptor ("uPAR"). The technology is expected to improve diagnosis and risk stratification in multiple cancer types.